scispace - formally typeset
Search or ask a question
Author

Gregorio T. Obrador

Bio: Gregorio T. Obrador is an academic researcher from Panamerican University. The author has contributed to research in topics: Kidney disease & Dialysis. The author has an hindex of 37, co-authored 78 publications receiving 11385 citations. Previous affiliations of Gregorio T. Obrador include Tufts University & Analytical Services.


Papers
More filters
Journal Article

2,609 citations

Journal Article
Andrew S. Levey1, Michael V. Rocco2, Sharon Anderson3, Sharon P. Andreoli4, George R. Bailie5, George L. Bakris6, Mary Beth Callahan, Jane H. Greene7, Cynda Ann Johnson8, James P. Lash9, Peter A. McCullough10, Edgar R. Miller11, Joseph V. Nally12, John D. Pirsch13, Ronald J. Portman14, Mary Ann Sevick15, Domenic A. Sica16, Donald E. Wesson17, Lawrence Y. Agodoa18, Kline Bolton19, Jeffrey A. Cutler18, Tom Hostetter18, Joseph Lau1, Katrin Uhlig1, Priscilla Chew1, Annamaria T. Kausz1, Bruce Kupelnick1, Gowri Raman1, Mark J. Sarnak1, Chenchen Wang1, Brad C. Astor11, Garabed Eknoyan, Adeera Levin, Nathan W. Levin, George R. Bailie5, Bryan N. Becker, Gavin J. Becker, Jerrilynn D. Burrowes, Fernando Carrera, David N. Churchill, Allan J. Collins, Peter W. Crooks, Dick DeZeeuw, Thomas A. Golper, Frank A. Gotch, Antonio M. Gotto, Roger Greenwood, Joel W. Greer, Richard H. Grimm, William E. Haley, Ronald J. Hogg, Alan R. Hull, Lawrence G. Hunsicker, Michael J. Klag, Saulo Klahr, Norbert Lameire, Francesco Locatelli, Sally McCulloch, Maureen Michael, John M. Newmann, Allen R. Nissenson, Keith C. Norris, Gregorio T. Obrador, William F. Owen, Thakor G. Patel, Glenda Payne, Claudio Ronco, Rosa A. Rivera-Mizzoni, Anton C. Schoolwerth, Robert A. Star, Michael W. Steffes, Theodore I. Steinman, John Pierre Wauters, Nanette K. Wenger, Josephine P. Briggs, Sally Burrows-Hudson, Derrick Latos, Donna Mapes, Edith Oberley, Brian J.G. Pereira, Kerry Willis, Anthony Gucciardo, Donna Fingerhut, Margaret Klette, Elicia Schachne 
TL;DR: The purpose of the Executive Summary is to provide a "stand-alone" summary of the background, scope, methods, and key recommendations, as well as the complete text of the guideline statements.

1,145 citations

Journal ArticleDOI
01 Jan 2012
TL;DR: The use of ESAs and other agents to treat anemia in CKD and methods for Guideline Development suggest that red cell transfusion is a viable treatment option.
Abstract: 282 Summary of Recommendation Statements 283 Chapter 1: Diagnosis and evaluation of anemia in CKD 288 Chapter 2: Use of iron to treat anemia in CKD 292 Chapter 3: Use of ESAs and other agents to treat anemia in CKD 299 Chapter 4: Red cell transfusion to treat anemia in CKD 311 Methods for Guideline Development 317 Biographic and Disclosure Information 324

712 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: The role of vitamin D in skeletal and nonskeletal health is considered and strategies for the prevention and treatment ofitamin D deficiency are suggested.
Abstract: Once foods in the United States were fortified with vitamin D, rickets appeared to have been conquered, and many considered major health problems from vitamin D deficiency resolved. But vitamin D deficiency is common. This review considers the role of vitamin D in skeletal and nonskeletal health and suggests strategies for the prevention and treatment of vitamin D deficiency.

11,849 citations

Journal Article
TL;DR: In the early 1990s, the National Kidney Foundation (K/DOQI) developed a set of clinical practice guidelines to define chronic kidney disease and to classify stages in the progression of kidney disease.

10,265 citations

01 Feb 2015
TL;DR: In this article, the authors describe the integrative analysis of 111 reference human epigenomes generated as part of the NIH Roadmap Epigenomics Consortium, profiled for histone modification patterns, DNA accessibility, DNA methylation and RNA expression.
Abstract: The reference human genome sequence set the stage for studies of genetic variation and its association with human disease, but epigenomic studies lack a similar reference. To address this need, the NIH Roadmap Epigenomics Consortium generated the largest collection so far of human epigenomes for primary cells and tissues. Here we describe the integrative analysis of 111 reference human epigenomes generated as part of the programme, profiled for histone modification patterns, DNA accessibility, DNA methylation and RNA expression. We establish global maps of regulatory elements, define regulatory modules of coordinated activity, and their likely activators and repressors. We show that disease- and trait-associated genetic variants are enriched in tissue-specific epigenomic marks, revealing biologically relevant cell types for diverse human traits, and providing a resource for interpreting the molecular basis of human disease. Our results demonstrate the central role of epigenomic information for understanding gene regulation, cellular differentiation and human disease.

4,409 citations

Journal ArticleDOI
TL;DR: The goal is to disseminate the simple definition and five-stage classification system of Chronic kidney disease, to summarize the major recommendations on early detection of chronic kidney disease in adults, and to consider some of the issues associated with these recommendations.
Abstract: Chronic kidney disease is a worldwide public health problem with an increasing incidence and prevalence, poor outcomes, and high cost. Outcomes of chronic kidney disease include not only kidney failure but also complications of decreased kidney function and cardiovascular disease. Current evidence suggests that some of these adverse outcomes can be prevented or delayed by early detection and treatment. Unfortunately, chronic kidney disease is underdiagnosed and undertreated, in part as a result of lack of agreement on a definition and classification of its stages of progression. Recent clinical practice guidelines by the National Kidney Foundation 1) define chronic kidney disease and classify its stages, regardless of underlying cause, 2) evaluate laboratory measurements for the clinical assessment of kidney disease, 3) associate the level of kidney function with complications of chronic kidney disease, and 4) stratify the risk for loss of kidney function and development of cardiovascular disease. The guidelines were developed by using an approach based on the procedure outlined by the Agency for Healthcare Research and Quality. This paper presents the definition and five-stage classification system of chronic kidney disease and summarizes the major recommendations on early detection in adults. Recommendations include identifying persons at increased risk (those with diabetes, those with hypertension, those with a family history of chronic kidney disease, those older than 60 years of age, or those with U.S. racial or ethnic minority status), detecting kidney damage by measuring the albumin-creatinine ratio in untimed ("spot") urine specimens, and estimating the glomerular filtration rate from serum creatinine measurements by using prediction equations. Because of the high prevalence of early stages of chronic kidney disease in the general population (approximately 11% of adults), this information is particularly important for general internists and specialists.

4,363 citations

Journal ArticleDOI
TL;DR: There was a high prevalence of CVD in CKD and that mortality due to CVD was 10 to 30 times higher in dialysis patients than in the general population, and the task force recommended that patients with CKD be considered in the “highest risk group” for subsequent CVD events.
Abstract: Chronic kidney disease1 (CKD) is a worldwide public health problem. In the United States, there is a rising incidence and prevalence of kidney failure, with poor outcomes and high cost. The number of individuals with kidney failure treated by dialysis and transplantation exceeded 320 000 in 1998 and is expected to surpass 650 000 by 2010.1,2 There is an even higher prevalence of earlier stages of CKD (Table 1).1,3 Kidney failure requiring treatment with dialysis or transplantation is the most visible outcome of CKD. However, cardiovascular disease (CVD) is also frequently associated with CKD, which is important because individuals with CKD are more likely to die of CVD than to develop kidney failure,4 CVD in CKD is treatable and potentially preventable, and CKD appears to be a risk factor for CVD. In 1998, the National Kidney Foundation (NKF) Task Force on Cardiovascular Disease in Chronic Renal Disease issued a report emphasizing the high risk of CVD in CKD.5 This report showed that there was a high prevalence of CVD in CKD and that mortality due to CVD was 10 to 30 times higher in dialysis patients than in the general population (Figure 1 and Table 2).6–18 The task force recommended that patients with CKD be considered in the “highest risk group” for subsequent CVD events and that treatment recommendations based on CVD risk stratification should take into account the highest-risk status of patients with CKD. View this table: TABLE 1. Stages of CKD Figure 1. Cardiovascular mortality defined by death due to arrhythmias, cardiomyopathy, cardiac arrest, myocardial infarction, atherosclerotic heart disease, and pulmonary edema in general population (GP; National Center for Health Statistics [NCHS] multiple cause of mortality data files International Classification of Diseases, 9th Revision [ICD 9] codes 402, 404, 410 to 414, and …

4,037 citations